My take on the 13D conference call -
They do think mighty highly of themselves.
January 10th 2020 the very first time Patterson ever heard anyone use the term immunologic virus a term that has been used for at least 30 years. He seems to be a little out of date on things.
Patterson cites an email from January 29th to Cytodyn about emerging threats and the immune system and "In many cases such as this coronavirus, all the damage is immune mediated.
On January 11th I made a post about using leronlimab to control pulmonary inflammation in serious cases of influenza. It's not like immune system disregulation and inflammation is any big secret.
Patterson's consulting agreement (or at least the one line he put up) - Scope of work - Clinical trial strategy including companion diagnostic needs. We all know how well that worked out.
Patterson also implies that as an employee of IncellDX he is free to assign inventions to it rather than Cytodyn because he is only a consultant. This is from the consultant agreement for Pestell -
Patterson says he was asked by Cytodyn about bringing IncellDX into the fold prior to the proposal email and says he didn't include it there. Why wouldn't he include it?
In the proposal letter he asks for $150 million in stocks and cash and milestone payments. One of the milestones is for Covid approval. Why would Cytodyn pay a milestone payment to IncellDX shareholders for approval on a drug Cytodyn owns and is doing the work to achieve approval on, it's complete nonsense.
Patterson also highlights "As we thought through the proposal you asked us to provide". It the same run around he was doing on twitter saying that Cytodyn wanted to buy IncellDX and asked us to provide a proposal. If Bruce first brought up selling the company (and we know it's been for sale since 2018) Cytodyn would have asked him for a proposal if they might have had any interest.
Patterson says "I don't know where the $350 million dollars comes from but it certainly doesn't come from this cover letter". Does he think nobody is going to see right through that? Of course ot wouldn't be detailed in the cover letter it would be detailed in the proposal it was attached too.
Patterson said there was a problem with tropism in the BLA submission while also saying he doesn't know what was in the RTF. If he doesn't know what was in the RTF then how can he know there was a problem with tropism? Tropism tests were done in both HIV trials since the beginning and the most widely used tropism test was employed.
Patterson says for the HIV trials look at the CD4 count but that is a secondary indicator the primary indicator is of course viral load. If anyone proposed to the FDA that CD4 should be used as the primary indicator in an HIV trial they'd be laughed out of the office.
Patterson says that Nader mistakenly saying tropism rather than receptor occupancy meant that Cytodyn wanted to replace tropism tests with RO tests because of expense is complete nonsense.
Patterson says the levels of CCR5 has to be known to do dosing. Sounds like an advertisement for his test kits. As his own tests show even at the massive levels of CCR5 in Covid, 700mg achieves 100% receptor occupancy.
In longhaulers talking about long-lived monocytes Patterson originally said they'd live 12 months, then it became 12-15 months, now it's 17 months. 10 years from now he'll be saying they're the only cells that have an infinite lifespan.
Patterson says they are the experts in longhaulers and can get an EUA for longhaulers in a very short time. If he knows so much why doesn't he know that an EUA would not be applicable to longhaulers?
Patterson says there are other drugs on the market similar to leronlimab for cancer. then why do trials for it? He does not know what he's talking about. He thinks leronlimab should be used with PD-L1 inhibitors. Leronlimab downregulates PD-L. If it does so sufficiently enough another inhibitor is unnecessary.
The cancer deals with big pharma are predicated on combining leronlimab with other drugs. Big pharma is not going to give Cytodyn money to use it in combotherapy unless it locks it in for exclusive use and forbids Cytodyn offering it for cancer as a standalone. The loss of sales to Cytodyn would be tremendous.
Patterson says "we aren't even going to talk about our thoughts on possible topical delivery for anti-inflammatories". He shouldn't talk about it because the bioavailability would be zero or near zero.
______________________________________________________
Rosenbaum sais that Patterson has funding for leronlimab longhaulers trial. Not quite, Patterson says he has been offered funding for longhaulers trials, not specifically for leronlimab trials. Since Patterson can't get leronlimab obviously it wasn't for leronlimab trials. If it was government money using other drugs why hasn't he accepted and started trials? Was the money offered by other pharma companies for their drugs?
Rosenbaum mentions Rentrak again what he doesn't say is that the board threw him out of the CEO position.
Rosenbaum says they have no interest in aligning with big pharma. Earlier in the broadcast Patterson said they did.
Beaty says Buyersstrike are putting out hit pieces and the 13d are not aligned in anyway. The 13d communiques (hit pieces) certainly have commonalities.
Errico says that the problems at Electrocore were due to a bad CEO and a bad Chairman of the Board. His brother JP Errico (a 13d member) was that CEO.
At least Rosenbaum admits how tenuous their attempted takeover of Cytodyn is.
Quote:our group is the only group in the world that can achieve this
They do think mighty highly of themselves.
January 10th 2020 the very first time Patterson ever heard anyone use the term immunologic virus a term that has been used for at least 30 years. He seems to be a little out of date on things.
Patterson cites an email from January 29th to Cytodyn about emerging threats and the immune system and "In many cases such as this coronavirus, all the damage is immune mediated.
On January 11th I made a post about using leronlimab to control pulmonary inflammation in serious cases of influenza. It's not like immune system disregulation and inflammation is any big secret.
Patterson's consulting agreement (or at least the one line he put up) - Scope of work - Clinical trial strategy including companion diagnostic needs. We all know how well that worked out.
Patterson also implies that as an employee of IncellDX he is free to assign inventions to it rather than Cytodyn because he is only a consultant. This is from the consultant agreement for Pestell -
Quote:Disclosure of Work Product. As used in this Agreement, the term “Work Product” means any copyrightable work of authorship. Consultant agrees to disclose promptly in writing to Company all Work Product that is solely or jointly authored by Consultant in the course of any work performed for Company (“Company Work Product”). Consultant agrees that any and all Company Work Product shall be the sole and exclusive property of Company.
Ownership of Work Product. Consultant hereby irrevocably assigns to Company all right, title and interest worldwide in and to the Company Work Product and all copyrights, trademarks, trade secrets and moral rights associated with such Company Work Product (the “Proprietary Rights”). Consultant retains no rights to use the Company Work Product and agrees not to challenge the validity of Company’s ownership in such Company Work Product. Consultant hereby grants to Company a non-exclusive, royalty-free, fully paid-up, irrevocable and world-wide right, with rights to sublicense through multiple tiers of sublicensees, to reproduce, make derivative works of, publicly perform, and publicly display in any form or medium (whether now known or later developed), distribute, make, use and sell any pre-existing intellectual property of Consultant incorporated or used in the Company Work Product in connection with its use of the Company Work Product.
Assistance. Consultant agrees to cooperate with Company or its designee(s), both during and after the term of this Agreement, to perfect and maintain Company’s copyright rights in and to the Company Work Product.
Patterson says he was asked by Cytodyn about bringing IncellDX into the fold prior to the proposal email and says he didn't include it there. Why wouldn't he include it?
In the proposal letter he asks for $150 million in stocks and cash and milestone payments. One of the milestones is for Covid approval. Why would Cytodyn pay a milestone payment to IncellDX shareholders for approval on a drug Cytodyn owns and is doing the work to achieve approval on, it's complete nonsense.
Patterson also highlights "As we thought through the proposal you asked us to provide". It the same run around he was doing on twitter saying that Cytodyn wanted to buy IncellDX and asked us to provide a proposal. If Bruce first brought up selling the company (and we know it's been for sale since 2018) Cytodyn would have asked him for a proposal if they might have had any interest.
Patterson says "I don't know where the $350 million dollars comes from but it certainly doesn't come from this cover letter". Does he think nobody is going to see right through that? Of course ot wouldn't be detailed in the cover letter it would be detailed in the proposal it was attached too.
Patterson said there was a problem with tropism in the BLA submission while also saying he doesn't know what was in the RTF. If he doesn't know what was in the RTF then how can he know there was a problem with tropism? Tropism tests were done in both HIV trials since the beginning and the most widely used tropism test was employed.
Patterson says for the HIV trials look at the CD4 count but that is a secondary indicator the primary indicator is of course viral load. If anyone proposed to the FDA that CD4 should be used as the primary indicator in an HIV trial they'd be laughed out of the office.
Quote:CD4 cell count is a weak surrogate endpoint
CD4 as endpoint
Patterson says that Nader mistakenly saying tropism rather than receptor occupancy meant that Cytodyn wanted to replace tropism tests with RO tests because of expense is complete nonsense.
Patterson says the levels of CCR5 has to be known to do dosing. Sounds like an advertisement for his test kits. As his own tests show even at the massive levels of CCR5 in Covid, 700mg achieves 100% receptor occupancy.
In longhaulers talking about long-lived monocytes Patterson originally said they'd live 12 months, then it became 12-15 months, now it's 17 months. 10 years from now he'll be saying they're the only cells that have an infinite lifespan.
Patterson says they are the experts in longhaulers and can get an EUA for longhaulers in a very short time. If he knows so much why doesn't he know that an EUA would not be applicable to longhaulers?
Patterson says there are other drugs on the market similar to leronlimab for cancer. then why do trials for it? He does not know what he's talking about. He thinks leronlimab should be used with PD-L1 inhibitors. Leronlimab downregulates PD-L. If it does so sufficiently enough another inhibitor is unnecessary.
The cancer deals with big pharma are predicated on combining leronlimab with other drugs. Big pharma is not going to give Cytodyn money to use it in combotherapy unless it locks it in for exclusive use and forbids Cytodyn offering it for cancer as a standalone. The loss of sales to Cytodyn would be tremendous.
Patterson says "we aren't even going to talk about our thoughts on possible topical delivery for anti-inflammatories". He shouldn't talk about it because the bioavailability would be zero or near zero.
______________________________________________________
Rosenbaum sais that Patterson has funding for leronlimab longhaulers trial. Not quite, Patterson says he has been offered funding for longhaulers trials, not specifically for leronlimab trials. Since Patterson can't get leronlimab obviously it wasn't for leronlimab trials. If it was government money using other drugs why hasn't he accepted and started trials? Was the money offered by other pharma companies for their drugs?
Rosenbaum mentions Rentrak again what he doesn't say is that the board threw him out of the CEO position.
Rosenbaum says they have no interest in aligning with big pharma. Earlier in the broadcast Patterson said they did.
Beaty says Buyersstrike are putting out hit pieces and the 13d are not aligned in anyway. The 13d communiques (hit pieces) certainly have commonalities.
Errico says that the problems at Electrocore were due to a bad CEO and a bad Chairman of the Board. His brother JP Errico (a 13d member) was that CEO.
At least Rosenbaum admits how tenuous their attempted takeover of Cytodyn is.
41
